AI governance is becoming increasingly important for pharmaceutical companies as AI is being used across research, clinical development, regulatory activities, medical affairs, and other high-stakes functions. It involves establishing the policies, processes, and controls needed to ensure AI is used responsibly and consistently. As these requirements become more complex, an AI governance platform can help pharma companies put those principles into practice within their existing workflows.
A governance document can define principles such as transparency, accountability, human oversight, and responsible AI use. But a policy sitting in a shared drive does not determine who reviews an AI output, what evidence supports it, when an issue must be escalated, or how an AI-assisted decision is documented.
For regulated organizations, governance needs to operate at the point where AI is actually being used.
The U.S. FDA's January 2026 principles for good AI practice in drug development emphasize a human-centric and risk-based approach, clear context of use, data governance and documentation, risk-based performance assessment, lifecycle management, and clear information about AI systems.
That points to a practical question for pharma leaders:
How do you turn AI governance from a policy into an operating model that people can actually follow?
1. Why a Governance PDF Isn't Governance
Most organizations start AI governance with a policy.
The document may define:
Approved AI uses
Prohibited uses
Data handling requirements
Human oversight
Privacy expectations
Model risk principles
Accountability
Documentation requirements
These are important foundations. But they do not automatically create operational control.
Imagine a regulatory affairs employee uses an AI system to analyze new FDA guidance.
The governance policy says that AI-generated information must be reviewed by a qualified professional.
What happens next?
Who reviews it?
What exactly do they check?
Where is their review recorded?
What happens if the AI cites an outdated source?
Who decides whether the output can be used?
When does the issue move to Legal, Quality, IT, or Regulatory?
If the organization cannot answer these questions, it has a governance policy but not yet a complete governance process.
NIST's AI Risk Management Framework makes a similar distinction by treating governance as a continuous organizational function rather than a one-time document. Its framework organizes AI risk management around Govern, Map, Measure, and Manage, with governance covering policies, accountability, legal requirements, monitoring, and organizational roles.
For pharma, this means governance should be embedded into the workflow itself.
2. Who Should Own AI Governance in Pharma?
AI governance rarely belongs to one department.
That is part of the challenge.
A pharmaceutical company may have several groups with legitimate responsibilities:
IT and Data: Infrastructure, security, architecture, access, integrations, and technical controls.
Legal: Privacy, intellectual property, contracts, liability, and emerging legal requirements.
Compliance: Policies, control frameworks, risk management, and adherence to organizational requirements.
Quality: Quality systems, documentation, validation expectations, and controlled processes.
Regulatory Affairs: Regulatory context, submission-related activities, agency expectations, and interpretation.
Medical Affairs: Scientific accuracy, medical review, external engagement, and appropriate use of medical information.
AI or Data Science: Model development, evaluation, performance monitoring, and technical risk.
The solution is not necessarily to create another committee that reviews every AI use case.
Instead, organizations need clear ownership by risk and workflow.
A low-risk productivity assistant may require relatively light review.
An AI system supporting regulatory intelligence or scientific evidence synthesis may require stronger source controls and expert review.
An AI system contributing to a regulated workflow may require additional validation, documentation, monitoring, and quality oversight.
The governance model should reflect those differences.
3. The Core Components of Operational AI Governance
A practical AI governance platform for regulated industries should translate governance principles into controls that users encounter during everyday AI work.
Human-in-the-loop review
Human oversight should not simply mean adding a disclaimer that says, "AI output must be reviewed."
The workflow should make review possible.
For example:
AI generates analysis → qualified reviewer checks evidence → reviewer approves or requests changes → output is released or escalated.
The reviewer should be able to see the underlying evidence and understand what they are being asked to approve.
This is particularly relevant to pharma because FDA's 2026 principles call for human-centric AI and emphasize assessing the complete system, including human-AI interactions.
Audit trails
Organizations should be able to reconstruct important AI-assisted activities.
Depending on the use case, that could include:
User
Date and time
AI system used
Information sources
Input or request
Generated output
Reviewer
Review decision
Changes made
Final approved version
The exact level of logging should be proportional to the risk of the workflow.
Model risk oversight
Governance should distinguish between different AI systems and use cases.
Questions should include:
What is the intended use?
What could go wrong?
What is the consequence of an incorrect output?
What data does the system access?
How is performance evaluated?
How frequently should it be reassessed?
NIST recommends testing AI systems before deployment and regularly during operation, with documented measurement and evaluation processes.
Access controls
Not every employee should have access to every AI capability or knowledge source.
Governance may need to control:
User roles
Data access
Approved sources
Sensitive information
AI applications
Administrative privileges
Export and sharing permissions
This is particularly important when AI systems connect internal knowledge with external information.
Figure: The core components of operational AI governance.
4. Mapping Governance Controls to Regulatory Expectations
Governance becomes easier to operationalize when organizations connect each control to a specific risk or requirement.
For example:
Governance Need | Operational Control |
Traceability | Source-linked outputs and audit logs |
Human accountability | Named expert review |
Data governance | Controlled sources and access permissions |
Performance assurance | Pre-deployment and ongoing evaluation |
Transparency | Clear documentation of AI use and limitations |
Risk management | Use-case classification and escalation |
Lifecycle control | Periodic review and change management |
The FDA's current good AI practice principles explicitly call for data source provenance, processing steps, and analytical decisions to be documented in a detailed, traceable, and verifiable manner. They also call for lifecycle monitoring and periodic reassessment.
The broader NIST AI RMF similarly calls for legal and regulatory requirements to be understood, managed, and documented, while defining clear organizational roles and responsibilities.
For organizations operating internationally, additional requirements may also apply. For example, the EU AI Act includes requirements for high-risk AI systems covering areas such as risk management, logging, documentation, information to deployers, human oversight, and robustness.
The practical lesson is important:
Compliance should not be treated as a document that sits beside the AI system. It should be reflected in how the system operates.
5. A Phased Roadmap for Implementing AI Governance
Trying to govern every AI application at once can create unnecessary complexity.
A phased approach is more practical.
Phase 1: Create an AI inventory
Start by identifying what already exists.
Document:
AI applications
Business owners
Data sources
Models
Users
Intended uses
Risk level
Deployment environment
You may find that the organization already has dozens of AI experiments operating outside a centralized governance process.
Phase 2: Classify use cases by risk
Create a simple risk framework.
For example:
Low risk: Administrative summarization or productivity assistance.
Medium risk: Internal scientific research and evidence synthesis.
High risk: AI supporting regulated decisions, submissions, safety assessments, or other high-impact workflows.
The exact classification should reflect the organization's risk tolerance and applicable requirements.
Phase 3: Establish review paths
Define who reviews what.
A medium-risk scientific workflow may require a qualified scientific reviewer.
A high-risk regulatory workflow may require Regulatory, Quality, or other designated experts.
Escalation should also be defined before a problem occurs.
Phase 4: Standardize documentation
Create consistent records for:
Intended use
Data sources
Model information
Risk assessment
Validation or evaluation
Human oversight
Known limitations
Changes
Monitoring
This creates institutional memory around AI systems.
Phase 5: Add continuous monitoring
Governance should continue after deployment.
Monitor:
Performance
Data changes
Model changes
User feedback
Errors
Incidents
Source changes
Emerging risks
NIST describes AI risk management as continuous and emphasizes ongoing monitoring and periodic review.
6. Common AI Governance Implementation Mistakes
Governance comes after deployment
One of the most common mistakes is allowing an AI application to reach production and then asking Compliance to determine how it should be governed.
Governance should be considered during design.
Ownership is unclear
If everyone is responsible, nobody may actually be accountable.
Every AI system should have an identifiable business owner and clearly defined technical, compliance, quality, and review responsibilities.
Human review is treated as a checkbox
A requirement saying "human review required" is insufficient if the reviewer cannot access the sources, understand the AI's limitations, or record their decision.
Documentation is created manually
If every AI workflow requires employees to create separate governance records manually, documentation can become inconsistent and quickly fall behind.
Where possible, governance evidence should be generated as part of the workflow.
Every AI application gets the same controls
Not every use case carries the same risk.
A governance framework should be risk-based rather than applying the heaviest controls to every application.
7. What Good Governance Looks Like in a Regulated Workflow
Consider a regulatory intelligence workflow.
A regulatory professional asks an AI system to identify recent developments relevant to a drug program.
A governed workflow could look like this:
1. Query
The user submits a defined research question.
2. Controlled retrieval
The system searches approved regulatory and scientific sources.
3. Evidence-backed analysis
The AI generates an answer with source attribution.
4. Expert review
A qualified regulatory professional reviews the findings and checks the interpretation.
5. Conflict resolution
If sources disagree, the reviewer can flag the conflict rather than accepting a single generated answer.
6. Approval
The reviewer records whether the output is accepted, revised, or escalated.
7. Audit trail
The workflow preserves the relevant evidence, output, review activity, and final decision.
This is what operational governance looks like.
The control is not a separate PDF.
The control is built into the work.
8. How Platform-Level Governance Can Operationalize These Controls
This is where an AI governance platform can provide value beyond a conventional policy framework.
Instead of asking employees to manually assemble evidence of compliance, platform-level controls can make governance part of the workflow.
If your team is already evaluating AI infrastructure, deployment models, or enterprise knowledge architecture, Pienomial’s KnolForge provides the foundation for building and deploying enterprise AI systems in a controlled, scalable environment. It brings together the infrastructure, knowledge, and governance capabilities needed to support enterprise AI use cases, helping teams decide which capabilities they need to own and which can be provided through a purpose-built platform.
For example, source attribution can make it easier for reviewers to verify where an AI-generated claim originated. KnolAI's product architecture emphasizes traceable research and evidence-linked outputs rather than treating generated answers as standalone text.
The platform can also connect research with expert review. Pienomial's KnolPersona is designed to support domain-expert review and validation, including regulatory, medical, and clinical expertise. It can be used as a review layer for AI-generated outputs, allowing experts to validate conclusions and provide structured feedback.
That creates a workflow such as:
Research → Evidence → AI analysis → Expert review → Revision or approval → Traceable record
This approach is particularly relevant to pharmaceutical organizations because the goal is not simply to generate an answer faster.
The goal is to make the answer verifiable, reviewable, and defensible.
9. Why Governance Should Live in the Platform
A policy tells employees what they should do.
A governed platform can help make the right action part of the workflow.
Consider the difference.
Policy-based approach:
"Users must verify AI-generated information against reliable sources."
Operational approach:
The AI output displays the supporting sources directly, allowing the reviewer to inspect the evidence before approving the result.
Or:
Policy-based approach:
"High-risk AI outputs require expert review."
Operational approach:
The workflow automatically routes designated outputs to an approved expert for review before they can move forward.
Or:
Policy-based approach:
"AI activity must be documented."
Operational approach:
The platform maintains the relevant research, evidence, review activity, and approval history as part of the workflow.
This is the fundamental shift from governance as documentation to governance as infrastructure.
10. Building an AI Governance Operating Model That Can Scale
As AI adoption expands, governance needs to scale without creating a manual approval bottleneck.
A mature operating model should establish four layers.
Governance layer
Defines policies, risk appetite, accountability, and decision rights.
Control layer
Implements access controls, review requirements, documentation, monitoring, and escalation.
Technology layer
Provides the infrastructure needed to enforce those controls.
People layer
Ensures qualified experts remain involved where scientific, regulatory, quality, or business judgment is required.
These layers should work together.
If governance exists only at the policy level, it may not influence everyday AI activity.
If governance exists only inside technology, it may fail to address organizational accountability.
The strongest model connects both.
Conclusion: Make Governance Part of the AI Workflow
Pharmaceutical companies do not need another AI policy that employees read once and then work around.
They need a governance model that operates where AI is actually being used.
That means defining ownership, classifying risk, controlling access, preserving evidence, documenting decisions, routing higher-risk outputs for expert review, and monitoring AI systems throughout their lifecycle.
The FDA's 2026 good AI practice principles and the NIST AI RMF both point toward this broader lifecycle approach: governance, documentation, human involvement, risk assessment, performance evaluation, and ongoing monitoring are interconnected activities rather than isolated compliance tasks.
For pharma organizations, the practical question is therefore not:
"Do we have an AI governance policy?"
It is:
"Can we demonstrate how governance operates when an employee actually uses AI?"
That is the standard technology and compliance leaders should work toward.
An AI governance platform can help make that transition by embedding evidence traceability, expert review, access controls, and auditability into the workflows themselves. Pienomial's KnolAI is built around this evidence-grounded approach, while KnolPersona provides an expert review layer for validating AI-generated intelligence.
For organizations evaluating how to operationalize AI governance across regulatory, medical, clinical, and other high-stakes workflows, the next step is to look beyond the policy document and examine the actual control points inside the AI workflow.
See how KnolAI's governance model works in practice.
